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Up to now, there are no curative therapies available for the subset of metastasized undiﬀerentiated/anaplastic thyroid carcinomas.
This review describes the possible use of immunocompetent cells which may help to restore the antitumor immune recognition
for treating an existing tumor or preventing its recurrence. The most prominent experimental strategy is the use of dendritic cells
(DCs) which are highly potent in presenting tumor antigens. Activated DCs subsequently migrate to draining lymph nodes where
they present antigens to na¨ ıve lymphocytes and induce cytotoxic T cells (CTL). Alternatively to DC therapy, adoptive cell transfer
may be performed by either using natural killer cells or ex vivo maturated CTLs. Within this review article we will focus on recent
advancesintheunderstandingofanti-tumorimmuneresponses,forexample,inthyroidcarcinomasincludingtheadvanceswhich
have been made for the identiﬁcation of potential tumor antigens in thyroid malignancies.
1.Introduction
The most frequently occurring forms of thyroid cancer
have a good prognosis. The neoplasms originate from two
distinct endocrine cell types of the thyroid gland: thyroid
hormone producing follicular epithelial cells and calcitonin-
producing parafollicular cells (C-cells). The most prevalent
thyroid cancer is that of papillary origin (PTC; about 60–
80%) it diﬀers from follicular (FTC; 15–25%) and anaplastic
carcinomas (ATC; 2–5%) but all are derived also from
follicular epithelial cells. Only about 3–10% of the thyroid
tumors derive from parafollicular C-cells. These tumors are
termed as medullary thyroid carcinoma (MTC) [1, 2].
The good prognosis of PTC and FTC is originally
attributed to the steady growth rate and the competence
of taking up iodide. This leads to the potential classical
therapeutic option of radioiodide (131I-) treatment after a
surgical revision of the tumor mass [3]. The varieties of the
diﬀerent tumors of follicular origin reveal in their distinct
morphology, their kind of metastatic spreading, and their
molecular alterations leading to diﬀerent pathways involved
in the boost of cell proliferation [4].
The carcinoma bearing the worst prognosis is ATC which
nearly almost derive de novo or rarely from pre-existing
PTC or FTC from which it may dediﬀerentiate sometimes
revealingtransitionalstages[5,6]and,however,maydevelop
into highly malignant ATC with low survival rates. ATC
have a high mitotic rate with both hematological and
lymphovascular invasions and do not retain any of the
biological features of the original follicular cells, such as
uptake of iodine and synthesis of thyroglobulin [7]. Due to
their molecular alterations and biological inoperable feature
these tumors are inaccessible to classical treatment options
such as radio- and chemotherapy [8]. New drugs, such as
fosbretabulin [9], bortezomib, and TNF-related apoptosis
induced ligand (TRAIL) [10] are now introduced and trialed
in clinical labs and human clinical studies.
Beside, MTC might also have a good prognosis when
it is restricted to the thyroid gland itself [11]. In case of
distant metastases moieties of the patients develop a rapidly
progressing disease leading to death. Clinical management of
this disease is possible only by monitoring the location and
expansion of the tumor mass and metastases followed by an
extensivesurgeryandbyobservingantigenslikecalcitoninor
carcinoembryonic antigen during the follow up [12].
Especially for the noncurative thyroid tumors such as
ATC and all invasive and metastasized PTC and FTC it is
of substantial interest to develop new approaches for the2 Journal of Oncology
treatmentofthesecancers.Here,wecanlearnfromimmuno-
logical interventions which have already been applied to
patients with other nonendocrine and endocrine cancers
including MTC.
2. Advances inCellularTherapy
An alternative approach for the treatment of cancers may
represent the use of cell vaccines aiming to activate the
immune system. Antitumor immunity is coordinated by
both innate and adaptive immunity, and mainly mediated
by cytotoxic T cells (CTLs), natural killer (NK), and natural
killer T (NKT) cells. The induction and coordination within
thiscontextisarrangedbydendriticcells(DCs)[13,14].DCs
are highly potent antigen-presenting cells with the ability of
taking up and processing tumor antigens in the peripheral
blood and tissues. They subsequently migrate to the draining
lymph nodes to present antigens to na¨ ıve T lymphocytes
and induce a cellular immune response by direct priming of
CD8+ CTLs and a cross-presentation involving CD4+ helper
cells. Moreover, DCs are also important in inducing humoral
immunity as explained by their capacity to activate na¨ ıve and
memory B cells [15]a n dN K[ 16]a sw e l la sN K Tc e l l s[ 17].
Thus, DCs can modulate the whole immune repertoire they
represent an excellent tool for treating an existing tumor or
preventing its recurrence.
In vivo, two main pathways of DC diﬀerentiation have
been described depending on their cell lineage and the tissue
were they are activated [18]. Under in vitro conditions,
myeloid DCs may be generated from monocytes by activat-
ing with granulocyte/macrophage colony-stimulating factor
(GM-CSF). The monocytes which encounter interleukin-
4 (IL-4) become DCs known as IL-4-DCs [19–21]. On
the other hand, monocytes diﬀerentiate into diﬀerent DC
subsetsaftercostimulation withother cytokines such asIFN-
α,T N Fo rI L - 1 5[ 22–28]. One essential precondition for the
success is the priming of DC with special tumor associated
antigens (TAA). These TAA must bear high immunogenic
properties against the background of HLA restriction. In
this context, the broadest experience has been gained for
the therapy of malignant melanoma [29–33]a sw e l la si n
renal cell carcinoma [34–38]. Even though only limited
success has been achieved from the clinical point of view,
DC vaccinations are superior compared to other antitumor
vaccination strategies [39]. Importantly, DC vaccination
strategies have steadily been improved by the number
of immunocompetent tumor antigens identiﬁed thus far
[40–43], even in endocrine malignacies [44]. One way of
assessing tumor antigens is based on the use of computer-
based algorithm software namely SYFPEITHI or BIMAS
[45–48] which helps to predict immunocompetent tumor
epitopes. Examples of classical tumor epitopes are those of
MAGE, GAGE, and NY-ISO1 in malignant melanoma [49–
55].
Alternatively to DC therapy, new strategies were intro-
ducedusingantigen-speciﬁcCTLsorpotentNKcellstoburst
the immune tolerance. Adoptive T-cell immunotherapy is
mainly performed by the generation of large numbers of
antigen-speciﬁc CTLs. But both tumor-speciﬁc CD4+ helper
1 (Th1) cells and cytotoxic CD8+ T cells might be generated
in vitro and administered directly to patients [56, 57].
Maturation of speciﬁc lymphocytes were performed by ex
vivo exposure to cytokines, HLA-restricted antigen epitopes,
and either in vitro generated DCs [57, 58]o rw i t hC D 3
and/or CD28-speciﬁc mAb [58, 59].
Ontheotherhand,NKcellsarethemajorrepresentatives
of the innate immune system that is regulated by positive
and negative mechanisms. NK cells interact with tumor
cells through activating receptors of the immunoglobulin
superfamily (NKp30, NKp44, NKp46, NKG2D) and the
lectin-like type II transmembrane proteins exhibiting a C-
type lectin domain (CD94, CD161), and on the other hand,
through inhibitory receptors (KIR, e.g., NKG2A) which
primarily bind to MHC class I antigens on target cells [60,
61]. Moreover, NK cells express CD16 which serves as a
receptor for antibodies to home on target cells performing
the antibody dependent cellular cytotoxicity [62, 63].
Within the last decade a multitude of diﬀerent studies
and clinical trails have been performed using cell therapies
[64–67]. Cancer immunotherapy using DC or adoptive
CTLs has much promise because malignant cells can be
aﬀected by the immune system without damaging healthy
tissue and without dangerous side eﬀects. Nevertheless,
careful monitoring of the elicited T-cell response and quality
assurance is mandatory to establish a rationale for speciﬁc
immunotherapy and to bring it from bench to bedside
[68, 69]. In any case, the identiﬁcation of tumor cell speciﬁc
antigens is crucial for establishing clinically eﬀective tumor
immunotherapies and monitoring the induced immune
response, including quantiﬁcation of antigen-speciﬁc CTLs.
Other approaches might use NK or NK-T cells, respectively,
however with less experiments compared to DC vaccinations
[70, 71].
3. ExperienceinCellularTherapies for
MedullaryThyroidCarcinoma
The idea of using polypeptide hormones as tumor antigens
for cancer therapy resulted from the observation in autoim-
munity, where responses to self tissue antigens led to tissue
damage. The most intensively investigated autoimmune
disease is T1DM, which is characterized by inﬁltration
of pancreatic islets by self-reactive lymphocytes, leading
to destruction of insulin-secreting β-cells. Insulin itself is
probably the most important autoantigen described thus far
[72]. This is supported by the fact that many reactive T cells
invading pancreatic islets are speciﬁc for immune insulin
epitopes and are capable of adoptively transferring diabetes
in non-obese diabetic (NOD) mice [73, 74].
This violability of the immune system leads to the option
to reconstitute immunity by antitumor immunotherapy.
One goal was scored by the work of Bradwell and Harvey
identifying the use of polypeptide hormones as tumor anti-
gens[75].Theywereﬁrsttoapplyacombinationofsynthetic
human and bovine parathyroid hormone (PTH) peptides
for vaccination of one patient with metastatic parathyroidJournal of Oncology 3
cancer. They demonstrated increased PTH-speciﬁc antibody
titers, resulting in a notable decrease in serum calcium levels
andareliefofclinicalsymptoms.Nonetheless,noassociation
with reduced tumor mass was observed. Thereafter, Betea
et al. [76] performed an immunization trial with bovine
and human PTH fragments and with intact full-length
human PTH. The eﬀect of this treatment was a speciﬁc
antibody production to all PTH fragments, resulting in
largely diminished PTH and serum calcium levels. Most
importantly, they observed a remarkable decrease in tumors
ofpulmonarymetastases,indicatingaPTHspeciﬁccytotoxic
immune response.
Basedonthisknowledge,thepolypeptidehormonecalci-
tonin has been proposed as tumor antigen for immunother-
apy in MTC. Since then, several vaccination trials have
been performed in murine models and as well in man.
Vaccination studies with CT-loaded DCs were performed
in a transgenic mouse model for MTC mice displaying the
identical mutation (substitution of Cys for Arg) within the
RET protooncogene at codon 634 as most patients with
multiple endocrine neoplasia type 2A [77, 78]. As in patients
with hereditary MTC, Ret/Cal mice develop diﬀuse C cell
hyperplasia and MTC with increased serum CT levels [77].
Depending on the CT epitopes used epitope speciﬁc CD8+
CTLs were visualized via tetramer analyses and by functional
lysis assays. These results were accompanied by a largely
diminished tumor outgrowth [79, 80].
In humans, several studies used full-length CT for prim-
ing DCs [81, 82]. Importantly, in one patient, a remarkable
transient regression of pulmonary and liver metastases was
seen. Detailed in vitro analyses revealed a CT-speciﬁc T-
cell reactivity, which was Th1-driven, in some patients, as
determined by a large increase in IFN-γ production [83].
Thereafter, a new protocol with interferon-α generated DCs
with direct tumor lysis activity was performed [84]. These
cells were also loaded with full-length CT [85]. After a long-
term follow-up of more than 48 months, two of ﬁve MTC
patientsshowedstablediseasewithchangesintumorsizeand
tumor marker of less than 25%. This is important because
it shows a direct connection between induction of cytotoxic
immunity and clinical response [85].
4. Potential Tumor Antigens in Poorly
Differentiated Thyroid Carcinomas
Tumor-associated antigens (TAA) are surface-associated
molecules such as receptors, transmembrane proteins or
secreted/membrane-attached peptides that are mostly cancer
speciﬁc, often overexpressed and recognized by the immune
system [120]. Therefore, identifying speciﬁc TAA is of key
importance for developing new options for immunotherapy
for incurable cancers. Up to now, however, no single TAA
for primary thyroid carcinomas have been proven but there
are a couple of candidates which might have the potential to
become one.
Potential tumor antigens which might represent a dis-
tinct tumor association can be divided into the groups of
classical cancer testes antigens, speciﬁc receptors, functional-
associated proteins, and metastases-associated proteins. Find
an assembly of potential TAA and of already performed
experiments in Table 1.
The most prominent tumor antigens are certainly the
cancer testes antigens, which have already been identiﬁed in
many malignancies and which have intensively used in the
context of immunotherapy [31–33, 40–42, 50–52]. These
antigens belong to a gene family which has been reported
t ob ee x p r e s s e di nt u m o rc e l l sb u tn o ti nn o r m a lt i s s u e s
aside from the testicular germ cells where the absence of
MHC class-I molecules protect the cells from testicular
autoimmunity, as the antigenic peptides are not be displayed
at the cell surface [121]. This makes these TAA so attractive
forimmunotherapysincenosideeﬀectsareexpected.InPTC
and FTC the cancer testis genes MAGE and GAGE were iden-
tiﬁed in human thyroid carcinomas [86–88]. For instance,
MAGE-3 is detectable in 29% of follicular tumor tissue and
in 80% in papillary thyroid carcinomas. This observation
explores the possibility of speciﬁc immunotherapy using
these TAA for vaccination trails.
Another group of potential tumor antigens represent
the large group of receptors. The main player are the IGF-I
receptor in thyroid carcinomas [89, 90, 122] and the receptor
tyrosine kinases as EGF-R, PDGF-R α & β,V E G F - R1 & 2 ,c -
K I Te s p e c i a l l yi nF T Ca n ds o m eA T C[ 91, 93, 94]. Whether
thesereceptorsarelikelytobeusedastumorantigenshasstill
to be proven. IGF-I is known to have signiﬁcant eﬀects on
cell proliferation and diﬀerentiation, it is a potent mitogen,
a powerful inhibitor of programmed cell death, and has
a well-established role in the transformation of normal to
malignant cells. So, especially the overexpression of the IGF-
I receptor might have a possible target function while its
presence is important for the development of a malignant
phenotype [89, 123]. Up to now, however, only antibody-
based therapies were performed [90, 124].
Other receptors untypically expressed in thyroid car-
cinomas might also be considered. For example, CD10
a common antigen for acute lymphoblastic leukemia has
been found to be useful in the diﬀerential diagnosis of
malignancy. Moreover, it has been shown to be expressed
in a group of PTC as well as in papillary microcarcinomas
[95] and in some FTC [96]. Several reports implicated the
chemokinereceptorCXCR4inthyroidtumoraggressiveness.
The target for CXCR4 is the chemokine CXCL12/SDF-1 α &
β involved in both embryonic and tumor angiogenesis [97].
This receptor might be also a potent target for a direct CTL
oﬀense.
In 2007, characteristic biomarkers were described for
PTC lymph node metastasis [98]. By real-time reverse
transcription-PCR and immunohistochemistry three genes
were discovered consistently overexpressed in lymph node
metastasis. Especially, LIM (kinase) domain containing 2
(LIMD2) and the protein tyrosine phosphatase receptor type
C (PTPRC also known as CD45) were signiﬁcantly diﬀerent
expressed in tumor samples versus metastatic samples.
Additionally, lymphotoxin beta (LTB), a type II membrane
anchored protein of the TNF family had borderline sig-
niﬁcance. Since there are no antibodies for LIMD2, only4 Journal of Oncology
Table 1: List of possible thyroid tumor associated antigens.
Methods
Tumor Potential TAA Biochemical in vivo
RT-PCR IHC Animal model Clinical trial
Cancer antigens
PTC MAGE × [86, 87] × [86–88]
FTC GAGE × [87] × [87]
Receptors
IGF-I R × [89] × [89, 90]
EGF-R × [91, 92]
PDGF-R × [93]
VEGF-R × [93, 94] × [94]
c-KIT × [93]
CD10 × [95, 96]
CXCR4 × [97]
LIMD2 × [98] × [98]
CD45 × [98] × [98]
LTB × [98] × [98]
Functional associated
Thyreoglobulin × [99–101]
HBME-1 × [102, 103]
CK19 × [101] × [102]
Galectins × [103]
Fibronectin-1 × [101] × [102]
Survivin × [104]
TERT × [105–107] × [108]
Metastases associated
MMPs × [109–111]
CD147 × [109]
u-PA/u-PA-R × [112, 113]
Fascin × [114]
ATC
Autotoxin × [115, 116]
CD133 × [117] × [117, 118]
MTC CT × [84] × [81, 82, 85]
PPCT × [80, 85]
CEA × [81, 82]
NY-ESO-1 × [119]
ATC: anaplastic thyroid cancer; FTC: follicular thyroid cancer; MTC: medullary thyroid cancer; PTC: papillary thyroid cancer.
MAGE/GAGE: melanoma antigens, also known as cancer testis antigen; IGF-I R: insulin growth factor-receptor; EGF-R: epidermal growth factor-receptor;
PDGF-R: plateled-derived growth factor-receptor; VEGF-R: vascular endothelial growth factor-receptor; c-KIT: hematopoietic stem cell receptor; CD10:
common acute lymphocytic leukemia antigen; CXCR4: stromal cell-derived factor 1 receptor; LIMD2: LIM kinase containing receptor-2; CD45: protein
tyrosine phosphatase receptor type C; LTB: lymphotoxin beta membrane anchored protein; HBME-1: human mesothelial cell marker 1; CK19: cytokeratin
19; TERT: telomerase reverse transcriptase; MMPs: matrix metalloproteinases; CD147: basigin, a subunit of the monocarboxylate transporter; u-PA and
u-PA-R: urokinase-type plasminogen activator and its receptor; CD133: hematopoietic stem cells antigen; CT: calcitonin; PPCal: preprocalcitonin; CEA:
carcinoembryonic antigen; NY-ESO-1: a cancer testis antigen.
RT-PCR: real-time PCR; IHC: immunohistochemistry.
PTPRC and LTB could be tested by immunohistochemistry.
All samples tested, showed both proteins in metastases and
little or no expression in primary tumor.
Moreover, there are the so-called functional-associated
antigens. PTC and FTC derive from thyroid epithelial cells
resulting in a large expression of thyreoglobulin which also
represent a classical tumor marker [99, 100, 125, 126].
Whether thyroglobulin also represents a tumor antigen
needs, however, to be proven.
Beside, a couple of other antigens have recently been
described for thyroid carcinomas. One of those is a
biomarker for the malignancy status of PTC and FTC. TheJournal of Oncology 5
human mesothelial cell marker 1 (HBME-1) have originally
been decribed in mesotheliomas. Meanwhile, it is known
that it is expressed in 90 to 100% of the carcinomas with a
strong membrane staining [102, 103]. Additionally, several
other antigens are on debate like human type I cytokeratin
19 (CK19), galectin-7, and probably galectin-3 which are
overexpressed in papillary and follicular malignancies [102,
127, 128]. CK19 is an acidic protein of 40 kDa that is part
of the cytoskeleton of epithelial cells and is highly expressed
by diﬀerentiated thyroid carcinomas, mainly of the papillary
subtype. The soluble fragments of CK19 can already be
measured by immunometric assays [129]. Galectins are
a structurally related family of lectin proteins that bind
speciﬁcally to beta-galactoside in a calcium-independent
manner; originally they are cytosolic proteins involved in
growth regulation and internal processes such as pre-mRNA
splicing [130] but they are able to translocate into vesicles
due to participate in cell-cell and cell-matrix adhesion [130,
131]. Moreover, elevated levels of ﬁbronectin-1 might be a
good target due to its alternative splicing during tumorigenic
process which leads to diﬀerent isoforms of extracellular
domains or connecting segments [101, 102]. Likewise, two
other TAA which have a broad expression pattern in many
types of human malignancies are now described in thyroid
carcinomas as well. One is survivin which is overexpressed in
poorly diﬀerentiated thyroid cancers inducing antiapoptotic
processes [104] and the telomerase reverse transcriptase
(TERT), that is, concomitant in cancer cells responsible for
the stabilization of the telomeres receiving an immortaliza-
tion of the respective cells [105–108]. Both antigens where
already used as targets for several vaccination studies in
melanomas and breast cancer [132–137].
Finally, there is the group of metastases-associated pro-
teins. The growth of a neoplasm and its ability to metas-
tasize is a multistep process dependent on angiogenesis
and immunological reactions of the organism. In this
process, adhesive factors like soluble intercellular adhe-
sion molecules (sICAM-1) and vascular cellular adhesion
molecules (sVCAM-1) are involved. The serum of peripheral
blood of patients with thyroid cancer before surgery revealed
these factors in a signiﬁcant higher concentration compared
to controls [138]. Since these soluble factors are egested
by the tumor itself and might also be associated to the
membrane exhibiting a potent tumor antigen.
Aside, several other factors are described being involved
in invasion and metastasis. One main component is the
group of matrix metalloproteinases (MMPs) since they dis-
rupt extracellular matrix proteins. An increase of circulating
MMP-2 [109, 110, 139, 140], MMP-7 [110, 111], and MMP-
9[ 110, 112, 141]w a sa ﬃrmed manifold. In this context,
CD147 one of the molecules involved in regulating the
expression MMP-2 was described to be expressed more
frequently in PTC and ATC patients and is associated
with their clinicopathologic features [109]. Additionally,
the urokinase-type plasminogen activator (u-PA) and its
speciﬁc receptor (u-PA-R) are involved in the disruption
of the extracellular matrix which relies on the activation
of plasminogen and an interaction with MMPs [112, 113].
One report advised on an antigen, namely, fascin which is
markedlyupregulatedinmorethan60%PTC.Itisdisplaying
an actin-bundling protein, however, associated with high-
grade extensive invasion [114].
5.SpecialSituationinAnaplastic
Thyroid Carcinoma
In ATC, a multitude of molecular alterations are found
[142, 143] but only a small number of potential antigens
have been described. Nonetheless, some potential antigens
discovered for FTC and PTC are also found in ATC although
molecular variances may also lead to a downregulation of
those. The most prominent loss is described for c-Kit which
was monitored to be absent in most ATC [144, 145].
Two additional proteins were recently found in ATC.
One is called autotaxin which has a nucleotide pyrophos-
phatase/phosphodiesteraseandlysophospholipaseDactivity.
It is usually secreted but also membrane-associated and
is a highly bioactive enhancer for motility of thyroid
tumors [115, 116]. Beside, expression of CD133 displaying
a hematopoietic stem cells antigen was described in tumor
derived cells lines [117, 118].
6.FuturePerspectives
The research for cellular cancer therapy has bred some
promising approaches but until now no single vaccination
regimen tested is indicated as a standard anticancer therapy.
In order to circumvent the escape of thyroid tumor cells
under T-cell pressure, polyvalent vaccination strategies may
help to overcome this situation. This goal can be achieved
by either loading DCs with a pool of peptide antigens which
might be individually identiﬁed as TAAs or by adoptive CTL
or NK/NK-T cell transfer. The major drawback in many
human malignancies including thyroid tumors is, however,
the lack of established tumor antigens which, in addition,
have already been applied in clinical context. As mentioned
above, a multitude of proteins and receptors have been
d e s c r i b e dt ob eo v e r e x p r e s s e di nac e r t a i np e r c e n t a g eo f
these thyroid tumors. Whether some of those are true TAAs
recognized from cells of the adaptive immune system is still
elusive and needs to be clariﬁed. Not till then, they could be
used in clinical trials in humans. Nonetheless, it is necessary
to search for other potential tumor antigens. Within this
context, novel technologies, that is, high-throughput gene
microarray, should further be implemented in order to
identify new antigens.
Another way of improving present treatment concepts
is to use a combination therapy by which tumor cells
are selectively aﬀected and the tumor escape mechanisms
are accessory blocked or decreased [146]. In this context,
conventional chemotherapy has already been supported by
a combination with DC vaccination showing some clinical
beneﬁts in nonendocrine tumors [147–149]. In endocrine
(e.g., thyroid) tumors such data does, however, not exist.
More relevant, however, might be a combination of cellular
immunotherapyandtyrosinekinaseinhibitors(TKIs)aﬀect-
ing target-speciﬁc agents. In thyroid malignancies diﬀerent6 Journal of Oncology
TKIs particularly sorafenib, motesanib, vatalanib, and so
forth,havealreadybeenappliedinclinicalstudies[150–152].
Although TKIs have been described to deplete immunoregu-
latory, for example, regulatory T cells they also have an eﬀect
o na l lTc e l l sa n dD C s[ 153, 154] but interestingly not on NK
cells [155]. On the other hand, TKIs’ aﬀect DCs to activate
NK cells [156–158]. The depletion of T cells by TKIs also
resulted in a reconstitution with a predominant expansion
of antigen-speciﬁc T cells [159] and the higher binding
capacity of CTLs to MHC presenting antigens [160]. So, the
combination of cellular therapies with targeted molecules
including TKIs hold promise for successful cancer therapies
in the future.
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